Basic Information
| LncRNA/CircRNA Name | POU5F1P1 |
| Synonyms | POU5F1B, OCT4-PG1, OCT4PG1, OTF3C, OTF3P1, POU5F1P1, POU5F1P4, POU5FLC20, POU5FLC8 |
| Region | GRCh38_8:127322183-127420066 |
| Ensemble | ENSG00000212993 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR etc. |
| Sample | prostate cancer tissues |
| Expression Pattern | up-regulated |
| Function Description | POU5F1P1 was found to be the only member of the POU5F1 family to be expressed in prostate with over-expression in prostatic carcinoma compared to surrounding prostatic tissue probably because of an increased density of expressing cells. The probability of a positive repeat biopsy increases with rising PCA3 scores. The PCA3 score was superior to %fPSA for predicting repeat prostate biopsy outcome and may be indicative of clinical stage and significance of pCa. |
| Pubmed ID | 20017164 |
| Year | 2010 |
| Title | POU5F1P1, a putative cancer susceptibility gene, is overexpressed in prostatic carcinoma. |
External Links
| Links for POU5F1P1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |